Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5′-deoxy-5-fluorouridine in tumour cells in vitro and in vivo

European Journal of Cancer

Volumn 38, Issue 5, 2002, Pages 712-717

  Nagata, T ^a,b   Nakamori, M ^a   Iwahashi, M ^a   Yamaue, H ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

5 Deoxy 5 fluorouridine (5 DFUR); Gene therapy; Pyrimidine nucleoside phosphorylase (PyNPase)

Indexed keywords

COMPLEMENTARY DNA; DOXIFLURIDINE; FLUOROURACIL; PYRIMIDINE NUCLEOSIDE PHOSPHORYLASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; COLON ADENOCARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TREATMENT OUTCOME; TUMOR CELL;

ADENOCARCINOMA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL SURVIVAL; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLOXURIDINE; FLUOROURACIL; GENE THERAPY; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PENTOSYLTRANSFERASES; PRODRUGS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036207299     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00469-5     Document Type: Article

References (39)

1. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer
2. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer
3. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer
4. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study
5. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study
6. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma
7. Fluorouracil and recombinant alfa-2a-interferon: An active regimen against advanced colorectal carcinoma
8. Interferon alpha and 5′-deoxy-5-fluorouridine in colon cancer: Effects as single agents and in combination on growth of xenograft tumours
9. Urinary TGFs1 in neoplasia: Immunoreactive TGF-alpha in the urine of patients with disseminated breast carcinoma
10. The therapeutic effects of orally administered 5′-deoxy-5-fluorouridine, 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil on experimental murine tumors
11. Enhanced therapeutic efficacy of 5′deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes
12. Selective inhibition of spontaneous pulmonary metastasis of Lewis lung carcinoma by 5′-deoxy-5-fluorouridine
13. A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma
14. Phase II study of doxifluridine in advanced colorectal adenocarcinoma
15. A Mr 43,000 epidermal growth factor-related protein purified from the urine of breast cancer patients
16. Detection of transforming growth factor alpha in human urine and plasma
17. Detection of urinary TGF-alpha by HPLC and western blot in patients with melanoma
18. The crystal structure of pyrimidine nucleoside phosphorylase in a closed conformation
19. Combination gene therapy for liver metastasis of colon carcinoma in vivo
20. Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity
21. Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity
22. Thymidine phosphorylase is angiogenic and promotes tumor growth
23. Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites
24. Thymidine phosphorylase expression in Kaposi sarcoma
25. Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues
26. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
27. Chemosensitivity testing with highly purified fresh human tumour cells with the MTT colorimetric assay
28. Chemosensitivity testing of human lung cancer cell lines using the MTT assay
29. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene
30. Toxicity of 5-fluorouracil
31. Comparative studies on the immunosuppressive effect among 5′-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil
32. 5′-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow
33. Distinct high-performance liquid chromatography pattern of transforming growth factor activity in urine of cancer patients as compared with that of normal individuals
34. Determination of transforming growth factor activity in effusions from cancer patients
35. Variant forms of rat epidermal growth factor present in the urine of nude rats bearing human tumors
36. 5-Fluorouracil increases susceptibility of renal cell cancer cell lines to lymphokine-activated killer cells: Evidence for alteration not at the level of recognition but at a post-binding stage of the lytic cycle
37. A dual anti-tumor effect of a combination of interferon-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity
38. Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA
39. Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: In vitro and in vivo study